Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2023-08-31 00:00:00 ET · period of report 2023-08-30 · accession 0001662579-23-000086 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-31 | 2023-08-30 | CCCC | Hirsch Andrew | Pres, CEO, Dir | M - OptEx | — | +7,500 | 116.1K | +7% | — |
| D | 2023-08-31 | 2023-08-30 | CCCC | Hirsch Andrew | Pres, CEO, Dir | F - Tax | $2.93 | -2,205 | 113.9K | -2% | -$6,461 |
| D | 2023-08-31 | 2023-08-30 | CCCC | Hirsch Andrew | Pres, CEO, Dir | M - OptEx | $0.00 | -7,500 | 55.0K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-30 | M | A | 7,500 | — | 116,106 | D | — | — | (F1) Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. |
| 2 | Common | Common Stock | 2023-08-30 | F | D | 2,205 | $2.93 | 113,901 | D | — | — | |
| 3 | Derivative | Performance Restricted Stock Units | 2023-08-30 | M | D | 7,500 | $0.00 | 55,000 | D | — · — to 2025-02-28 | 7,500 Common Stock | (F1) Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. |